<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Converted PDF</title>
</head>
<body>
<p>Since January 2020 Elsevier has created a COVID - 19 resource centre with</p>
<p>free information in English and Mandarin on the novel coronavirus COVID -</p>
<p>19. The COVID - 19 resource centre is hosted on Elsevier Connect, the</p>
<p>company's public news and information website.</p>
<p>Elsevier hereby grants permission to make all its COVID - 19 - related</p>
<p>research that is available on the COVID - 19 resource centre - including th is</p>
<p>research content - immediately available in PubMed Central and other</p>
<p>publicly funded repositories, such as the WHO COVID database with rights</p>
<p>for unrestricted research re - use and analyses in any form or by any means</p>
<p>with acknowledgement of the o riginal source. These permissions are</p>
<p>granted for free by Elsevier for as long as the COVID - 19 resource centre</p>
<p>remains active.</p>
<p>Thrombosis Research 202 (2021) 17–23 Available online 8 March 2021 0049-3848/© 2021 Elsevier Ltd. All rights reserved. Incidence and mortality due to thromboembolic events during the Suleman Aktaa a , b , c , * , Jianhua Wu a , d , Ramesh Nadarajah a , b , c , Muhammad Rashid e , f , John Deanfield f , g , Mamas A. Mamas e , h , Chris P. Gale a , b , c a Leeds Institute for Data Analytics, University of Leeds, UK b Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK c Department of Cardiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK d Division of Clinical and Translational Research, School of Dentistry, University of Leeds, Leeds, UK e Keele Cardiovascular Research Group, Centre for Prognosis Research, Institutes of Applied Clinical Science and Primary Care and Health Sciences, Keele University, UK f National Institute of Cardiovascular Outcomes Research (NICOR), Barts Health NHS Trust, UK g Institute of Cardiovascular Sciences, University College London, UK h Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, UK ARTICLE INFO Keywords: ABSTRACT Background: - - * Corresponding author at: Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds LS2 9JT, UK. Contents lists available at ScienceDirect Thrombosis Research journal homepage: www.else vier.com/loc ate/thromres https://doi.org/10.1016/j.thromres.2021.03.006 Evidence supports an excess of deaths during the COVID-19 pandemic. We report the incidence and</p>
<p>Mark de Belder COVID-19 Thrombo-embolic events mortality of thrombo-embolic events (TE) during the COVID-19 pandemic. Methods: Received 20 December 2020; Received in revised form 6 February 2021; Accepted 1 March 2021 COVID-19 pandemic: Multi-sourced population-based health records cohort study E-mail address: Multi-sourced nationwide cohort study of adults (age s.aktaa@leeds.ac.uk (S. Aktaa). ≥ 18 years) admitted to hospital with TE and</p>
<p>deaths from TE in England (hospital and community) between 1st February 2018 and 31st July 2020. Relative Mortality</p>
<p>Pulmonary embolism risks, adjusted for age, sex, atrial fibrillation, co-morbidities and time trend comparing before and during the COVID-19 pandemic were estimated using Poisson regression.</p>
<p>Findings: Of 272,423 patients admitted with TE to 195 hospitals, 86,577 (31.8%) were admitted after 2nd March</p>
<p>2020 (first COVID-19 death in the UK). The incidence of TE hospitalised increased during the COVID-19 pandemic from 1090 to 1590 per 100,000 (absolute risk change 45.9% [95% CI 45.1 – 46.6%], adjusted rela</p>
<p>tive risk [ARR] 1.43 [95% CI 1.41 – 1.44]) driven particularly by pulmonary embolism; 1.49, 95% CI 1.46 – 1.52.</p>
<p>TE were more frequent among those with COVID-19; 1.9% vs. 1.6%, absolute risk change 21.7%, 95% CI 21.0 – 22.4%, ARR 1.20, 95% CI 1.18 – 1.22. There was an increase in the overall mortality from TE during the</p>
<p>pandemic (617, 6.7% proportional increase compared with the historical baseline), with more TE deaths</p>
<p>Interpretation: occurring in the community compared with the historical rate (44% vs. 33%). The COVID-19 pandemic has resulted in an increase in the incidence of hospitalised TE. There were</p>
<p>more deaths from TE in the community highlighting a number of mechanisms including the hypercoagulable</p>
<p>state associated with COVID-19 infection and potential impact of delays in seeking help. Research in context: Evidence before this study</p>
<p>We searched PubMed on 16 November 2020 for articles that documented the incidence and mortality of</p>
<p>navirus* ” thrombo-embolic events (TE) during the COVID-19 pandemic using the search terms OR “ 2019-nCOV ” OR “ SARS-CoV ” AND ( “ Thromboembolism ” OR “ Venous Thromboembolism ” “ COVID-19 ” OR “ Coro OR</p>
<p>“ thromboembol* ” ) with no language or time restrictions. The majority of data on TE in COVID-19 pertains to</p>
<p>associated with an increased mortality rate (adjusted hazard ratio 1.82; 95% CI 1.54 hospitalised patients from retrospective cohort studies. One study found that TE in hospitalised patients was – 2.15). A systematic review</p>
<p>and meta-analysis of 35 studies in 9249 hospitalised patients calculated an overall pooled incidence of TE of</p>
<p>17.8% (95% CI: 9.9 The most contemporary data are from a cohort of 1114 patients (715 outpatient, 399 hospitalised, 170 admitted – 27.4%), rising to 22.9% (95% CI: 14.5 – 32.4%) in patients admitted to intensive care (ICU).</p>
<p>to ICU). With robust COVID-19-specific therapies and widespread thromboprophylaxis the prevalence of venous</p>
<p>TE in ICU patients was reported as 7% ( n = 12) when catheter-/device-related events were excluded, and among</p>
<p>Available online 8 March 2021</p>
<p>0049-3848/© 2021 Elsevier Ltd. All rights reserved.</p>
<p>Thrombosis Research 202 (2021) 17–23 18 the outpatients there was no TE reported. No published studies have used nationwide data to investigate TE 1. Introduction - - - - - - - - - S. Aktaa et al. embolism [PE] and deep venous thrombosis [DVT]). Patients with acute</p>
<p>during the pandemic or the effect of the pandemic on outcomes of patients with TE but without Covid-19. Added value of this study Thrombo-embolism has been described as one of the major cardio coronary syndrome (ACS) were excluded from the analysis, because data on acute CV events, including ACS have been reported elsewhere [ 15 ].</p>
<p>This retrospective multi-sourced nationwide unlinked cohort study compares the overall incidence and mortality vascular (CV) complications of coronavirus disease 19 (COVID-19)</p>
<p>contributing to worse outcomes [ 1 linked to SARS-CoV-2, which causes COVID-19, could predispose of TE prior to and during the COVID-19 pandemic. We found an increased incidence of TE despite only a small proportion having a diagnosis of COVID-19. This may highlight the lack of testing, particularly in the community – 6 ]. Pathophysiological mechanisms 2.2. Death data</p>
<p>infected people to arterial and venous thrombo-embolic events (here during the initial phase of the pandemic, and the possibility of other factors contributing to TE risk, such as We obtained all certified and registered deaths in England for</p>
<p>to viraemia [ 7 after collectively referred to as TE), including the inflammatory response from TE was higher in the community during the pandemic and this highlights that adverse societal effects of the decreased daily activity mandated by home quarantine and alterations in medication concordance. Mortality – 10 ], endothelial function disorder in the lung as else deceased 2020 as recorded in the Civil Registration Deaths Data of the Office for ≥ 18 years of age, between 1st February 2018 and 31st July</p>
<p>where [ 11 ], and the hypercoagulable state described in COVID-19 pa pandemic, such as aversion to seeking medical assessment, may precipitate worse outcomes related to TE. National Statistics (ONS) [ 17 ]. We used the ICD-10 codes corresponding</p>
<p>tients [ 4 , 12 ]. The pandemic may also have had unintended consequences associated with changes in health seeking behaviour, Implications of all the available evidence Evidence suggests that COVID-19 produces a hypercoagulable state and thromboprophylaxis is recommended in to the immediate cause of death and contributing causes as registered on the Medical Certificate of Cause of Death (MCCD) regardless of the</p>
<p>which could affect the potential to prevent and treat TE in people not hospitalised patients to prevent excess mortality from TE. Whether to anticoagulate non-hospitalised ambulatory location of death. The MCCD is completed by the doctor who attended</p>
<p>system to the pandemic may, therefore, be associated with excess deaths infected with-COVID-19 [ 12 ]. The response of the public and the health patients with COVID-19 will be answered by ongoing trials. Clinicians should consider the risks posed by decreased daily activity and fear of medical contact, and provide appropriate advice to patients. the deceased during their last illness within 5 days unless there is to be a coroner ’ s post-mortem or an inquest. TE directly leading to death were</p>
<p>secondary to TE in the community, which has been reported for a range categorised as venous (PE and DVT), and arterial, and then deaths were</p>
<p>of other CV conditions [ 13 The United Kingdom is unique in that it has a suite of continuous – 16 ]. classified according to the COVID-19 status. ICD-10 codes ‘U071 (confirmed) and ‘U072 ’ (suspected) were used to identify whether a ’</p>
<p>capture, full populace, nationwide datasets such as the Civil Registration Deaths Data and Hospital Episode Statistics (HES). During the pandemic, death was related to COVID-19 on any part of the MCCD. The place of</p>
<p>these datasets have demonstrated critical value in showing how the death as recorded on the MCCD was classified as community (home, care home and hospice) or hospital.</p>
<p>inform mitigation strategies now that a second wave has occurred. pandemic has affected the health of people and with a potential to</p>
<p>This study aimed to investigate, using nationwide data from HES and 2.3. Statistical analyses</p>
<p>the Civil Registration Deaths Data in England, the patterns of change in admissions with different phenotypes of TE, as well as the causes and Baseline characteristics were described using numbers and percent</p>
<p>place of TE-related deaths antecedent, compared with during the ages for categorical data. Data were stratified by COVID-19 status (infected or not infected), age band ( &lt; 50, 50 – 59, 60 – 69, 70 – 79, 80 +</p>
<p>COVID-19 pandemic. We hypothesised that patients may differ during the pandemic as a result of a new pathology - high ’ characteristics years), sex and Charlson co-morbidity index (CCI) [ 18 ]. Since AF is</p>
<p>lighting the hypercoagulable state associated with the COVID-19 associated with TE, such as ischaemic stroke, the incidence of different TE phenotypes were each adjusted for AF incidence. Given that there</p>
<p>deaths occurring in the community because of the changes in health- contagion. Furthermore, we anticipated an increase in TE-related was a decline in admission during the pandemic [ 14 , 19 , 20 ], we esti</p>
<p>seeking behaviour during the pandemic. mated the proportion of TE admissions (adjusted for presence of AF) from all admissions in the corresponding day for the previous two years</p>
<p>2. Methods and compared this with the proportion of TE admissions from all ad</p>
<p>missions in the corresponding day from 2nd March 2020. This date was chosen for the time series comparison because it corresponded to the</p>
<p>2.1. Data collection first COVID-19 death in the UK.</p>
<p>HES consists of International Statistical Classification of Disease- admissions. The number of daily deaths was presented using a 7-day Incidence rates for admission with TE were standardised per 100,000</p>
<p>10th Revision (ICD-10) codes regarding demographical, clinical, administrative and patient information of all patients admitted to any simple moving average (the mean number of daily deaths for that day</p>
<p>hospital in England. We identified TE on the basis of the ICD-10 codes and the preceding 6 days) from 1st February up to 31st July, adjusted for seasonality. A Poisson regression model was fitted to estimate the rela</p>
<p>patients hospitalised between 1st February 2018 and 31st July 2020 and (Supplement Table 1) recorded at the principle or primary position for tive risk, adjusted for age, sex, AF, CCI, and time trend (before and after</p>
<p>included only the index hospitalisations for TE during the study period the COVID-19 pandemic). For the categories of TE death, the ICD-10 code on the MCCD was</p>
<p>in the analysis; to avoid analysing replicate events for the same patient, re-hospitalisations due to TE during the study period were excluded. counted only once per deceased. Thus, the overall rate of TE death represents the number of people with a direct TE-related death. In light</p>
<p>Admissions with TE were classified as arterial (including stroke and of the fact that people may have had more than one of the predefined TE</p>
<p>arterial thromboembolic events), and venous (including pulmonary events leading to death, analyses for each of the predefined TE</p>
<p>Thrombosis Research 202 (2021) 17–23 19 categories represent the number of events (not people) per category. For - - - - Table 1 Study period COVID-19 status Note: frequency (percentage) was reported for each category. TE, thrombo- Table 2 Incidence rate (per a Adjusted b Conditions Pre- a A Poisson regression model was used to calculate the relative risk, accounted b A Poisson regression model was used to calculate the relative risk, adjusted S. Aktaa et al. Absolute risk COVID- Percentage Unadjusted RR (95% CI) RR (95% 2.0% during the pandemic, equating to 500 more people being hospi</p>
<p>for age, sex, COVID-19 status, Charlson Comorbidity Index and time trend. TE, thromboembolic events; DVT, deep vein thrombosis; PE, pulmonary embolism. for time trend. thrombo-embolic events between 1st Feb 2018 and 31st July 2020, by study Patient characteristics for admissions in England with arterial and venous Before COVID- embolic events; DVT, deep vein thrombosis; PE, pulmonary embolism. Incidence rates, absolute risk change and adjusted relative risk between pre- COVID-19 and COVID-19 periods. 100,000) relative risk the purposes of this investigation, TE that contributed, but did not directly lead to death were excluded from the analyses. The TE-related COVID- 19 COVID-19 change 19 period COVID-19 (95% CI) relative risk COVID-19 CI) talised with TE per 100,000 admissions (absolute risk increase 45.9% [95% CI 45.1 – 46.6%], adjusted relative risk 1.43 [95% CI 1.41 – 1.44])</p>
<p>period (pre-COVID-19 and during COVID-19), and COVID-19 status. 19 period All excess death rate was derived by subtracting total TE deaths during period + ve -ve ( Table 2 ). While the most frequent manifestation of TE related to arterial</p>
<p>N 185,846 86,577 84,728 1849 Women (%) 90,904 (48.9) 41,453 the COVID-19 pandemic up to the end of the period of analysis and the average total TE deaths in the same time period of 2018 and 2019. patients 40,594 859 pathologies, there was an increase in all types of TE. The largest increase was seen in venous TE (adjusted relative risk 1.44, 95% CI 1.42 – 1.47)</p>
<p>TE 1090 1590 45.9% All tests were two sided and statistical significance considered as (47.9) (47.9) (45.1 – 46.6%) (46.5) 1.42 (1.41 – 1.43) p &lt; 1.43 (1.41 – and in particular PE (1.49, 95% CI 1.46 1.44) – 1.52) during, compared with</p>
<p>Age (%) 0 – 49 22,943 (12.4) 10,944 0.05. Statistical analyses were performed in R V.4.0.0. Arterial 720 1036 43.8% 10,760 184 1.40 1.42 before, the pandemic ( Figs. 1, 2 ). Moreover, adjustment for de mographics and co-morbidities, including AF, made little difference to</p>
<p>3. Results TE Venous 369 554 50.0% (12.8) (12.8) (42.9 – 44.7%) (10.2) (1.39 – 1.46 1.41) (1.40 – 1.44 the direction or magnitude of the relative increase in TE admissions 1.44)</p>
<p>50 – 59 21,837 (11.8) 10,850 3.1. Admissions TE (12.6) 10,651 (12.7) (48.6 – 51.3%) 199 (11.0) (1.45 – 1.48) (1.42 – ( Table 2 , Supplement Fig. 1). 1.47) TE were more frequent among those diagnosed with COVID-19</p>
<p>60 – 69 31,920 (17.3) 15,146 DVT 164 233 42.2% 14,846 (40.3 – 44.1%) 300 1.48 (1.46 – 1.50) 1.46 (1.42 – infection, 1.9% vs. 1.6%, absolute risk change 21.7% 95% CI 1.49)</p>
<p>70 – 79 47,039 (25.5) 21,829 TE codes from 195 National Health Service (NHS) hospitals in England PE 205 329 60.8% Data were available for 272,423 admissions relating to pre-specified (17.6) (17.7) 21,380 (16.6) 449 1.54 1.49 21.0 – The greatest increase in TE risk with COVID-19 infections was observed 22.4% (adjusted relative risk 1.20, 95% CI 1.18 – 1.22) ( Figs. 1, 2 ).</p>
<p>over the 3-year study period. Of those, 86,577 (31.8%) patients were admitted during the COVID-19 pandemic and 132,357 (48.6%) were (25.4) (25.4) (59.0 – 62.7%) (24.9) (1.52 – 1.56) (1.46 – in venous TE (1.87, 95% CI 1.85 greatest risk increase (2.96, 95% CI 2.91 1.52) – 1.89), with PE demonstrating the – 3.00) (Supplement Table 2).</p>
<p>80 + 60,603 (32.9) 27,059 women. The age, co-morbidities and TE phenotypes of patients admitted (31.5) 26,389 (31.4) 670 (37.2)</p>
<p>Charlson with TE prior to the pandemic were comparable to those for patients admitted during it ( Table 1 ). 3.2. Deaths</p>
<p>comorbidity index There was an increase in the standardised incidence rate of admis</p>
<p>0 31,611 (17.0) 14,711 sions with TE during the COVID-19 pandemic. When compared with the background number for all admissions during these two periods, TE 14,455 256 5476 deaths relating to TE in the community and hospital settings, During the COVID-19 pandemic study period, there were 4374 and</p>
<p>1 43,147 (23.2) 18,572 accounted for 1.4% of all hospital admissions before the pandemic and (17.0) (17.1) 18,287 (13.8) 285 respectively ( Fig. 3 ). In the community, this represented a 1289 (30%)</p>
<p>(21.5) (21.6) (15.4) increase in the deaths compared with the average for the same period in 2018 and 2019. In hospital, there was a 672 (11%) decrease in TE-</p>
<p>2 36,159 (19.5) 16,050 15,771 279 related deaths in the same time period. Both arterial and venous TE</p>
<p>3 26,739 (14.4) 12,611 (18.5) (18.6) 12,307 (15.1) 304 accounted for the increase in TE-deaths in the community during the pandemic, as shown in Fig. 3 . However, arterial TE contributed to the</p>
<p>(14.6) (14.5) (16.4) greatest excess in death. Deaths from TE were more frequent among</p>
<p>4 + 48,190 (25.9) 24,633 (28.5) 23,908 (28.2) 725 (39.2) patients not diagnosed with COVID-19, compared with patients who had the infection (5.6% vs. 1.5%).</p>
<p>Atrial fibrillation 36,413 (19.6) 16,708 16,223 485</p>
<p>Arterial TE (%) 119,373 (64.2) 55,166 (%) (19.3) (19.1) 53,975 (26.2) 1191 4. Discussion</p>
<p>(63.7) (63.7) (64.4) This nationwide study describes, using full populace data, the inci</p>
<p>Venous TE (%) 66,473 (35.8) 31,411 (36.3) 30,753 (36.3) 658 (35.6) dence and mortality attributed to TE during the COVID-19 pandemic compared with previous years. We have illustrated that the pandemic</p>
<p>DVT (%) 30,586 (16.5) 13,852 13,712 140 (7.6) has resulted in an increase in the incidence of all phenotypes of TE, and</p>
<p>PE (%) 35,575 (19.1) 17,767 (16.0) (16.2) 17,162 605 was associated with an abrupt rise in TE-related deaths. Nearly half of these deaths occurred in the community, with estimated rates being</p>
<p>(20.5) (20.3) (32.7)</p>
<p>Thrombosis Research 202 (2021) 17–23 20 substantially higher than those of previous years. During the COVID-19 - - - - - - Fig. 1. S. Aktaa et al. Incidence rates of thromboembolic events, by the type of thromboembolic event and COVID-19 status. increase in the incidence of TE despite only 2.2% having a diagnosis of</p>
<p>including stroke, but the highest risk increase was observed in venous pandemic, the most frequent phenotype of TE in England was arterial, TE; thrombo-embolic events. COVID-19. This is important because testing for COVID-19 was insuffi cient in the early stages of the pandemic both in the hospital setting</p>
<p>TE, particularly PE, with only a small proportion being confirmed [ 31 , 32 ] and in the community [ 33 ]. In addition, some patients may have</p>
<p>COVID-19 cases. Although infection with SARS-COV-2 was associated with an increase in TE, deaths from TE were more frequent among those had false negative results for COVID-19 [ 34 ]. Thus, and given that the greatest magnitude of increased TE risk during the pandemic was seen in</p>
<p>not diagnosed with COVID-19, possibly signifying a lack of testing for venous TE, our study suggests that other factors such as decreased daily</p>
<p>COVID-19 during the first stage of the pandemic, particularly in the community setting. activity mandated by home quarantine - so called ‘seated immobility syndrome ’ - [ 35 ] and alterations in medication concordance [ 12 ] may</p>
<p>This research provides insights into potential mechanisms behind the have contributed to the increased incidence of TE during the COVID-19</p>
<p>baseline characteristics of those admitted with TE were similar during excess in deaths during the COVID-19 pandemic. We showed that the pandemic. The current study shows that while the mortality of TE declined in</p>
<p>compared with before the pandemic, suggesting that TE most affect hospital, it increased substantially in the community during the</p>
<p>more frequent among patients diagnosed with COVID-19, and that patients classically at risk. In addition, our study illustrated that TE were pandemic. This supports the findings of an earlier report which sug gested that the COVID-19 outbreak was associated with a sharp rise in</p>
<p>adjusting for co-morbidities made little difference to the direction or magnitude of this association. As such, our findings support the notion the number of out-of-hospital deaths related to TE [ 36 ]. This rise in TE- deaths – so called mortality harvesting – which occurred in the com</p>
<p>that COVID-19 predisposes to TE both within and outside the pulmonary munity highlights how adverse societal effects of the pandemic, such as</p>
<p>vasculature. While this predisposition may be partially explained by the historical risk-factors for TE, other mechanisms may exist, such as the aversion to seeking medical assessment, may precipitate worse out comes in TE, and raises the possibility that a second mechanism – delay</p>
<p>distortion of the endothelial thrombotic/fibrinolytic balance, inflam by the public in seeking help for fear of catching COVID-19 in hospital</p>
<p>matory storm, and alveolar injury [ 11 , 21 ]. These processes can contribute to immunothrombosis in situ [ 22 , 23 ], and may explain the [ 15 ]. TE associated deaths in patients with confirmed COVID-19 infection</p>
<p>substantial increase in PE incidence observed in our study, as well as are likely to be underestimated in our study given the lack of testing</p>
<p>that previously reported in venous TE in the context of COVID-19 despite the use of thromboprophylaxis [ 6 , 24 ]. during the early phases of the pandemic [ 31 , 32 ], and the reliance on ONS data [ 37 ]. However, the observed increase in TE mortality in non-</p>
<p>Previous studies have described the incidence and outcomes of TE in COVID patients highlights the potential indirect repercussions of the</p>
<p>patients hospitalised with confirmed COVID-19 infection [ 6 , 25 study extends this knowledge by comparing the overall incidence and – 29 ]. Our pandemic on TE management and outcomes. While these findings may be explained by insufficient detection and diagnosis of COVID-19</p>
<p>mortality of TE prior to and during the COVID-19 pandemic, as well as infection, other factors may have contributed. That is, sub-optimal</p>
<p>ated with an increase in TE - supporting the notion of COVID-19 by COVID-19 status. Infection with the SARS-COV-2 virus was associ treatment of non-COVID patients at risk of TE because of the pressures of the pandemic on healthcare services, and the late presentation to</p>
<p>precipitating a prothrombotic state [ 12 , 30 ]. Yet, we also found an hospital of patients with TE will have adversely affected prognosis [ 15 ].</p>
<p>Thrombosis Research 202 (2021) 17–23 21 Although our study has many strengths, it nonetheless has some - - Fig. 2. S. Aktaa et al. Incidence rates of DVT and PE events, by COVID-19 status. capture non-fatal TE that occurred during the hospital stay for patients</p>
<p>limitations. The exclusion of ICD codes for ACS may have resulted in an underestimation for the overall impact of the COVID-19 on the incidence DVT, deep vein thrombosis; PE, pulmonary embolism. admitted with a non-TE illness during the pandemic.</p>
<p>of TE. However, given that these data have been previously described 5. Conclusion</p>
<p>[ 15 ], we opted to present here the rates of venous TE, as well as other non-coronary arterial TE during the pandemic. Another limitation is that This nationwide analysis of hospitalisations and deaths from TE</p>
<p>non-fatal TE that did not lead to hospitalisation were not captured in our during the COVID-19 pandemic found an increase in the incidence of all</p>
<p>study. The MCCD were completed by any doctor (not just the attending doctor) during the COVID-19 pandemic and the duration of time over phenotypes of TE, particularly PE and a rise of TE-related deaths in the community. The increased incidence of TE during the pandemic and</p>
<p>which the deceased was not seen before referral to the coroner was with COVID-19 infection, which appeared not to be associated with</p>
<p>extended from 14 to 28 days. Moreover the documentation of causes of death could be ‘to the best of their knowledge and belief ’ without people having different co-morbidities, suggests a hypercoagulable state associated with the infection. The rise in death in the community during</p>
<p>diagnostic proof, if appropriate and to avoid delay [ 38 ]. This may have the pandemic, compared with previous years, highlights possible fears</p>
<p>resulted in misclassification bias, with under-reporting of the deaths directly due to TE disease in preference to COVID-19 infection (which is around or delays in seeking help.</p>
<p>a notifiable disease under the Health Protection (Notification) Regula tions 2010) or respiratory disease. Our analysis will have excluded a Data sharing statement</p>
<p>small proportion of deaths under review by the coroner, though typi We used routinely collected data from electronic health records</p>
<p>cally these will have been unnatural in aetiology. Equally, coding of TE in HES may be inaccurate, and our study may have under-estimated the using HES data to obtain information about TE hospitalisation, and death register to obtain mortality data. The ICD codes used are provided</p>
<p>incidence of TE. That is because we only included TE at the principle or in the supplementary material. Data used for this study will be available</p>
<p>primary position of hospital admission diagnoses, and, thus, did not upon approval by NHS Digital UK.</p>
<p>[6] G. Piazza, U. Campia, S. Hurwitz, et al., Registry of arterial and venous thromboembolic complications in patients with COVID-19, J. Am. Coll. Cardiol. 76</p>
<p>(18) (2020) 2060 – 2072 .</p>
<p>[7] J.T. Merrill, D. Erkan, J. Winakur, J.A. James, Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications, Nat. Rev. Rheumatol. 16 (10)</p>
<p>(2020) 581 – 589 .</p>
<p>[8] G.B. Danzi, M. Loffi, G. Galeazzi, E. Gherbesi, Acute pulmonary embolism and COVID-19 pneumonia: a random association? European Heart Journal 41 (19)</p>
<p>[9] F. Zhou, T. Yu, R. Du, et al., Clinical course and risk factors for mortality of adult (2020) 1858 .</p>
<p>inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet</p>
<p>[10] H. Li, L. Liu, D. Zhang, et al., SARS-CoV-2 and viral sepsis: observations and 395 (10229) (2020) 1054 – 1062 . Thrombosis Research 202 (2021) 17–23</p>
<p>hypotheses, Lancet 395 (10235) (2020) 1517 – 1520 .</p>
<p>[11] P. Libby, T. Lüscher, COVID-19 is, in the end, an endothelial disease, Eur. Heart J. 41 (32) (2020) 3038 – 3044 .</p>
<p>[12] B. Bikdeli, M.V. Madhavan, D. Jimenez, et al., COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and</p>
<p>follow-up. &lt; span class = “ subtitle ” &gt;&lt; em &gt; JACC &lt; /em &gt; State-of-the-Art Review &lt; /</p>
<p>[13] A.P. Kansagra, M.S. Goyal, S. Hamilton, G.W. Albers, Collateral effect of Covid-19 span &gt; 75 (23) (2020) 2950 – 2973 .</p>
<p>on stroke evaluation in the United States, N. Engl. J. Med. 383 (4) (2020) 400 – 401 .</p>
<p>[14] M.M. Mafham, E. Spata, R. Goldacre, et al., COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England, Lancet 396</p>
<p>[15] J. Wu, M.A. Mamas, M.O. Mohamed, et al., Place and causes of acute (10248) (2020) 381 – 389 .</p>
<p>cardiovascular mortality during the COVID-19 pandemic, Heart 107 (2021)</p>
<p>[16] J. Wu, M.A. Mamas, M.A. de Belder, J.E. Deanfield, C.P. Gale, Second decline in 113 – 119, heartjnl-2020-317912 .</p>
<p>admissions with heart failure and myocardial infarction during the COVID-19</p>
<p>[17] User guide to mortality statistics, Available, https://www.ons.gov.uk/peoplepopu pandemic, J. Am. Coll. Cardiol. 77 (8) (2021) 1141 – 1143 .</p>
<p>lationandcommunity/birthsdeathsandmarriages/deaths/methodologies/use rguidetomortalitystatisticsjuly2017 .</p>
<p>[18] M.E. Charlson, P. Pompei, K.L. Ales, C.R. MacKenzie, A new method of classifying</p>
<p>Thrombosis Research 202 (2021) 17–23 22 Funding [1] A.C. Spyropoulos, J.I. Weitz, Hospitalized COVID-19 patients and venous Fig. 3. S. Aktaa et al. Daily number of thromboembolic related deaths, by the type of thromboembolic event and place of death. prognostic comorbidity in longitudinal studies: development and validation, J. Chronic Dis. 40 (5) (1987) 373 – 383 .</p>
<p>[2] A. Gupta, M.V. Madhavan, K. Sehgal, et al., Extrapulmonary manifestations of TE; thrombo-embolic events. None. thromboembolism, Circulation 142 (2) (2020) 129 – 132 . [19] J. Wu, M. Mamas, M. Rashid, et al., Patient response, treatments, and mortality for</p>
<p>[3] E. Driggin, M.V. Madhavan, B. Bikdeli, et al., Cardiovascular considerations for COVID-19, Nat. Med. 26 (7) (2020) 1017 – 1032 . acute myocardial infarction during the COVID-19 pandemic, European Heart Journal - Quality of Care and Clinical Outcomes (2020) 1 – 9 .</p>
<p>Ethical approval patients, health care workers, and health systems during the COVID-19 pandemic, [20] M.D. Solomon, E.J. McNulty, J.S. Rana, et al., The Covid-19 pandemic and the incidence of acute myocardial infarction, N. Engl. J. Med. 383 (7) (2020) 691 – 693 .</p>
<p>[4] N. Tang, D. Li, X. Wang, Z. Sun, Abnormal coagulation parameters are associated Not applicable. J. Am. Coll. Cardiol. 75 (18) (2020) 2352 – 2371 . [21] S.X. Gu, T. Tyagi, K. Jain, et al., Thrombocytopathy and endotheliopathy: crucial</p>
<p>CRediT authorship contribution statement with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. [22] Nicolai L, Leunig A, Brambs S, et al. Vascular neutrophilic inflammation and contributors to COVID-19 thromboinflammation, Nat. Rev. Cardiol. (2020) 1 – 16 .</p>
<p>[5] D. Liao, F. Zhou, L. Luo, et al., Haematological characteristics and risk factors in the Haemost. 18 (4) (2020) 844 – 847 . immunothrombosis distinguish severe COVID-19 from influenza pneumonia.</p>
<p>and MR performed the data cleaning and data analysis. RN conducted SA and CPG were responsible for the study design and concept. JW classification and prognosis evaluation of COVID-19: a retrospective cohort study, Journal of Thrombosis and Haemostasis; n/a(n/a).</p>
<p>the literature search. SA and CPG wrote the first draft of the manuscript The Lancet Haematology 7 (9) (2020) e671-e8 .</p>
<p>and all authors participated in the writing of the paper.</p>
<p>Declaration of competing interest</p>
<p>None.</p>
<p>Appendix A. Supplementary data</p>
<p>Supplementary data to this article can be found online at https://doi.</p>
<p>org/10.1016/j.thromres.2021.03.006 .</p>
<p>References</p>
<p>S. Aktaa et al.</p>
<p>Thrombosis Research 202 (2021) 17–23 23 [23] L.F. van Dam, L.J.M. Kroft, L.I. van der Wal, et al., Clinical and computed [31] D. Oliver, David Oliver: Let ’ s be open and honest about covid-19 deaths in care</p>
<p>tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Thromb. Res. 193 (2020) 86 – 89. [32] S. Griffin, Covid-19: homes, BMJ 369 (2020) m2334. “ staggering number ” of extra deaths in community is not</p>
<p>[24] J. Poissy, J. Goutay, M. Caplan, et al., Pulmonary embolism in patients with COVID-19, Circulation 142 (2) (2020) 184 – 186. [33] G. Iacobucci, Covid-19: lack of capacity led to halting of community testing in explained by covid-19, BMJ 369 (2020) m1931.</p>
<p>[25] W. Thomas, J. Varley, A. Johnston, et al., Thrombotic complications of patients march, admits deputy chief medical officer, BMJ 369 (2020) m1845.</p>
<p>Kingdom, Thromb. Res. 191 (2020) 76 admitted to intensive care with COVID-19 at a teaching hospital in the United – 77. [34] Variation in false-negative rate of reverse transcriptase polymerase chain reaction – based SARS-CoV-2 tests by time since exposure, Annals of Internal</p>
<p>[26] S.K. Kunutsor, J.A. Laukkanen, Incidence of venous and arterial thromboembolic Medicine 173 (4) (2020) 262 – 267.</p>
<p>complications in COVID-19: a systematic review and meta-analysis, Thromb. Res. 196 (2020) 27 – 30. [35] K. Hitos, M. Cannon, S. Cannon, S. Garth, J.P. Fletcher, Effect of leg exercises on popliteal venous blood flow during prolonged immobility of seated subjects:</p>
<p>[27] T.J. Oxley, J. Mocco, S. Majidi, et al., Large-vessel stroke as a presenting feature of implications for prevention of travel-related deep vein thrombosis, J. Thromb.</p>
<p>[28] S. Bilaloglu, Y. Aphinyanaphongs, S. Jones, E. Iturrate, J. Hochman, J.S. Berger, Covid-19 in the young, N. Engl. J. Med. 382 (20) (2020), e60. [36] J. Benzakoun, G. Hmeydia, T. Delabarde, et al., Excess out-of-hospital deaths Haemost. 5 (9) (2007) 1890 – 1895.</p>
<p>Thrombosis in hospitalized patients with COVID-19 in a New York City health system, JAMA 324 (8) (2020) 799 – 801. during the COVID-19 outbreak: evidence of pulmonary embolism as a main determinant, Eur. J. Heart Fail. 22 (6) (2020) 1046 – 1047.</p>
<p>[29] J. Helms, C. Tacquard, F. Severac, et al., High risk of thrombosis in patients with [37] V.S. Raleigh, Tackling UK ’ s mortality problem: covid-19 and other causes, BMJ</p>
<p>severe SARS-CoV-2 infection: a multicenter prospective cohort study, Intensive Care Med. 46 (6) (2020) 1089 – 1098. [38] Guidance for doctors completing medical certificates of cause of death in England 369 (2020) m2295.</p>
<p>[30] M. Ackermann, S.E. Verleden, M. Kuehnel, et al., Pulmonary vascular and Wales, Available, https://assets.publishing.service.gov.uk/government/uploa</p>
<p>endothelialitis, thrombosis, and angiogenesis in Covid-19, N. Engl. J. Med. 383 (2) (2020) 120 – 128. ds/system/uploads/attachment_data/file/877302/guidance-for-doctors-completi ngmedical-certificates-of-cause-of-death-covid-19.pdf.</p>
</body>
</html>
